New Zealand markets closed

FibroGen, Inc. (FGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.5800+0.1400 (+5.74%)
At close: 04:00PM EDT
2.6100 +0.03 (+1.16%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4400
Open2.4600
Bid2.5300 x 500
Ask2.6100 x 1000
Day's range2.3000 - 2.6800
52-week range0.3330 - 20.9000
Volume1,845,399
Avg. volume2,627,211
Market cap254.83M
Beta (5Y monthly)0.66
PE ratio (TTM)N/A
EPS (TTM)-2.9200
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.25
  • Zacks

    Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

    Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

  • GlobeNewswire

    FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

    SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference. The live audio webcast of the event will be available to investors and other interested p

  • Zacks

    Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

    Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.